150,246 members

Skip to content. | Skip to navigation


Future health technology assessments in oncology


Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.

Future health technology assessments in oncology

Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such as immunotherapies.

In recent critiques of economic models in this area by the National Institute for Health and Care Excellence (NICE), long-term cancer survivors who have received such treatments were unlikely to report quality of life (QoL) scores which are similar to, or higher than, those of equivalent general population samples. This literature review examines whether there is evidence to support the assumption that the quality of life of long-term cancer survivors can be similar to that of age/sex-matched population samples.